The Effect of GLP-1 on the Inhibition of Glucagon Secretion

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Type 2 DiabetesType 1 Diabetes
Interventions
DRUG

Native human Glucagon-like Peptide-1 ( GLP-1(7-36))

"Continuous iv. infusion of the native gut hormone GLP-1 (0.2 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"

DRUG

NaCl

Continuous iv. saline infusion (NaCl Isotonic) for 210 minutes. Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)

DRUG

Native human Glucagon-like Peptide-1 ( GLP-1(7-36))

"Continuous iv. infusion of the native gut hormone GLP-1 (0.4 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"

DRUG

Native human Glucagon-like Peptide-1 ( GLP-1(7-36))

"Continuous iv. infusion of the native gut hormone GLP-1 (0.8 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"

Trial Locations (1)

DK-2900

Gentofte University Hospital, Hellerup

All Listed Sponsors
lead

University Hospital, Gentofte, Copenhagen

OTHER

NCT01507597 - The Effect of GLP-1 on the Inhibition of Glucagon Secretion | Biotech Hunter | Biotech Hunter